DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
-71.16%
US · US
CCL.US latest organized financial period shows revenue lacks a complete YoY comparison and net income grew +44.05% YoY. Current price is about 25.48 USD, while the model base case is about 44.76 USD; the current price sits -43.1% versus the base case. The page shows both reported and adjusted views; valuation still defaults to reported figures, while adjusted figures help isolate structured one-time-item impact. This summary is intended for public-information research and model review.
Annual financial metrics with switchable views. · Unit: USD
Price date: 2026/04/29 · Updated: 2026/04/29 15:25
Hover each model row to inspect formulas and inputs.
-43.09%
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
-71.16%
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
-62.58%
Solves the forward FCF growth rate implied by the current price.
Current price implies roughly -0.3% annualized FCF growth.
Estimates earnings power value without assuming growth.
+18.82%
Updated: 2026/04/29 15:25
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/11/30 | Restructuring charges | Restructuring | -10M USD | Medium |
| 2024/11/30 | Restructuring charges | Restructuring | -17M USD | Medium |
| 2023/11/30 | Asset impairment | Impairment | -33M USD | Medium |
| 2023/11/30 | Restructuring charges | Restructuring | -15M USD | Medium |
| 2022/11/30 | Asset impairment | Impairment | -1B USD | Medium |
| 2021/11/30 | Asset impairment | Impairment | -2B USD | Medium |
| 2020/11/30 | Asset impairment | Impairment | -10B USD | Medium |
| 2024/08/31 | Asset impairment | Impairment | -3M USD | Medium |
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/11/30 | Annual | - | 3B USD | 3B USD | 3B USD | 2.02 | 2.03 |
| 2024/11/30 | Annual | - | 2B USD | 2B USD | 1B USD | 1.44 | 1.45 |
| 2023/11/30 | Annual | - | -74M USD | -26M USD | 997M USD | -0.06 | -0.02 |
| 2022/11/30 | Annual | - | -6B USD | -5B USD | -7B USD | -5.16 | -4.22 |
| 2021/11/30 | Annual | - | -10B USD | -8B USD | -8B USD | -8.46 | -6.7 |
Profit after costs, expenses, interest, and taxes.
Adjusted close trend. Current price sample covers: 2025/04/16 - 2026/04/29.